Kubota Pharmaceutical will sell specially designed glasses dubbed Kubota Glass, which it claims are able to reverse the effects of myopia.
The glasses shine tiny lights at the retina to simulate short-distance blurring, forcing the user to look further ahead and in doing so taking the pressure of the axial deformation of eyeballs.
Long-term testing is still required to gauge how effective Kubota Glass is at this in detail, but studies so far suggest that they are at least effective at curbing the progression of myopia.
Kubota Glass has been approved as a medical device in Taiwan and the USA.
Kubota Pharmaceutical charges 770,000 yen for a pair of Kubota Glass while offering a 100-percent satisfaction guarantee.
According to 2009 research conducted by Japan's Ministry of Education, Culture, Sports, Science, and Technology, around 25% of first-graders had less than perfect eyesight, with the percentage rising to 50% among sixth-graders.


SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
Jared Isaacman Confirmed as NASA Administrator, Becomes 15th Leader of U.S. Space Agency
How the war in Iran is already affecting UK farmers and food production
Google's TurboQuant Sends South Korean Chip Stocks Tumbling Amid AI Memory Demand Fears
Tabletop particle accelerator could transform medicine and materials science
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Is dark chocolate healthier than milk chocolate? 2 dietitians explain
Oil Prices Slip as Trump Extends Iran Ceasefire Deadline Amid Ongoing War Fears
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain
Bank of Japan Unveils New Inflation Gauge to Support Case for Future Rate Hikes
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 



